Sanofi’s Icaria combo extends progression-free survival in multiple myeloma at Phase 3
pharmafile | February 6, 2019 | News story | Research and Development | Icaria, Sanofi, multiple myeloma, pharma
Sanofi has continued to make progress in the development of Icaria (isatuximab), with the company announcing that the therapy met its primary endpoint in combination with pomalidomide and low-dose dexamethasone in the treatment of relapsed/refractory multiple myeloma compared to the standard care.
A Phase 3 study for the treatment incorporated 307 participants across 96 centres in 24 countries who had previously received two or more anti-myeloma therapies, including at least two consecutive cycles of lenalidomide and a proteasome inhibitor given alone or in combination, confirmed that the combo succeeded in prolonging progression-free survival.
Further details were not given, but Sanofi revealed that full data form the study would be presented at an upcoming medical meeting, with regulatory submissions to come later in the year.
The second most common type of haematologic cancer, multiple myeloma affects around 17,500 in the UK, with approximately 5,500 new diagnoses each year.
“There is a continuing need for new therapeutic options for multiple myeloma in patients who have either relapsed or are no longer responding to their current treatment,” explained Professor Kwee Yong, UK Icaria Trial Investigator and Professor of Haematology at University College London Hospital. “The ICARIA study confirms that the investigational agent, isatuximab, in combination with the current standard of care, pomalidomide, improves outcomes for these patients and I’m excited about how these data demonstrate the ability of this investigational compound to extend disease free life in patients living with relapsed/refractory multiple myeloma.”
Dr Marc Moodley, Medical Director for Sanofi Genzyme, added: “There is an unmet need in the management of relapsed/refractory multiple myeloma and the Icaria data represents a significant milestone for Sanofi Genzyme and our oncology portfolio. The isatuximab development programme continues to progress and we are committed to bringing this investigational compound forward as a potential new therapeutic option for patients as soon as possible.”
Matt Fellows
Related Content
Heidelberg Pharma gains FDA ODD for ATAC candidate
Heidelberg Pharma has announced that it has gained Orphan Drug Designation (ODD) from the US …
Sanofi shares phase 2b results for dermatitis treatment
Sanofi has shared positive results from part 2 of the investigational phase 2b STREAM-AD study …
GSK shares results from phase 3 trial for Blenrep for treatment of multiple myeloma
GSK has announced positive results from an interim analysis of the DREAMM-8 phase 3 head-to-head …
